Status:
COMPLETED
Minoxidil Response Testing in Males With Androgenetic Alopecia
Lead Sponsor:
Applied Biology, Inc.
Conditions:
Androgenetic Alopecia
Eligibility:
MALE
18-49 years
Brief Summary
Topical minoxidil is the most common drug used for the treatment of AGA in men. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population remains relatively low i....
Eligibility Criteria
Inclusion
- Males in overall good health
- Age: 18 to 49
- Diagnosed with male androgenetic alopecia with vertex pattern IIIv, IV, or V on the Norwood Hamilton Scale
- Willing to have a mini dot tattoo placed in the target area of the scalp
- Willing to maintain the same hair style, color, shampoo and hair products use, and approximate hair length throughout the study
- Able to give informed consent
- Able to comply with the study requirements for 16 consecutive weeks
Exclusion
- Previous adverse event from topical minoxidil treatment
- Does not use and have not used in the past 6 months anti-androgen therapy such as finasteride
- Does not use and have not used in the past 6 months minoxidil (topical or oral)
- Does not take medication known to cause hair thinning such as Coumadin and anti-depressants/anti-psychotics
- Folliculitis
- Scalp psoriasis
- Seborrheic dermatitis
- Inflammatory scalp conditions such as lichen planopilaris
Key Trial Info
Start Date :
July 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2018
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT02198261
Start Date
July 1 2014
End Date
October 1 2018
Last Update
October 5 2018
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Physicians Hair Institute
Tucson, Arizona, United States, 85719
2
Tennessee Clinical Research Center
Nashville, Tennessee, United States, 37215
3
Sinclair Dermatology
East Melbourne, Australia, 3002
4
LTM Medical College & Hospital
Mumbai, India, 400022